By April 17, 2002, only 15 million doses of
aging smallpox vaccine were found. However, when tested in human
volunteers at a dilution of one to five, that vaccine successfully immunized
99 percent of tested subjects, thus increasing the supply of smallpox
vaccine from 15 million to 57 million doses. Further, even when the
vaccine was diluted tenfold, the results proved efficient in 97 percent
of those inoculated and now yielded 150 million doses of vaccine. The
pharmaceutical firm Aventis Pasteur found and donated an additional
85 million doses. Finally, the government ordered from a private company,
Acambis, an additional 155 million vaccine doses. Hence, the drive
was accelerated to obtain, store, and use smallpox vaccine.
UPDATE 3-Sanofi to buy vaccine maker Acambis for $548 mln - Reuters
Jul 25, 2008 - Sanofi-Aventis SA (SASY.PA)agreed on Friday to buy British vaccine maker Acambis PlcACM.L for 276 million pounds ($547.8 million), in a dealhighlighting big drug companies' hunger for biotech assets.